zimberelimab,domvanalimab,etrumadenant
Arcus Biosciences,Gilead,Otsuka
['pivotal trial', 'nsclc', 'pivot,io,i', 'sclc', ' arcus ', 'gilead']
at #asco23, together with arcus biosciences, we re presenting updated results from our #nsclc study that includes the first fc-silent anti-tigit investigational monoclonal antibody in pivotal trials. 
The impossible is not impossible. It’s simply what hasn’t been achieved yet. Twitter guidelines: https://t.co/vWkdtfUf7N